The global cell culture market was valued at USD 29.51 billion in 2025. The market is projected to grow from USD 32.02 billion in 2026 to USD 73.8 billion by 2034, exhibiting a compound annual growth rate of 11% during the forecast period. Contrive Datum Insights presents this information in its report titled "Cell Culture Market Size, Share & Industry Analysis, By Consumable (Minimum Essential Media (MEM), RPMI 1640 Media, DMEM/F-12 Media, F-10 Serum Free Media, BME Media, Insect Media, Other Media, Fetal Bovine Serum, Other AnimalSerum, Albumin, Other), Product (Culture Systems, Incubators, Centrifuges, Cryostorage Equipment, Biosafety Equipment, Pipetting Instruments), Application (Biopharmaceuticals, Tissue Culture & Engineering, Vaccine Production, Drug Development, Gene Therapy, Toxicity Testing, Cancer Research, Others), End user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs)/CDMOs, Hospitals & Diagnostic Laboratories), Cell type (Mammalian Cell Culture, Non-Mammalian Cell Culture), and Regional Forecast, 2026-2034".
Cell culture refers to the process of growing cells outside their natural environment under controlled laboratory or manufacturing conditions, supported by a defined set of media, sera, reagents, and equipment. Buyers span biopharmaceutical and biotechnology manufacturers producing therapeutic proteins and vaccines, academic and research institutes conducting basic and applied research, and contract research and development organizations supporting external sponsor programs. The category covers both the consumable inputs, growth media, serum, and specialty reagents, that cells require at every passage, and the equipment, incubators, biosafety cabinets, and culture systems, used to grow and maintain them.
Expansion of monoclonal antibody and recombinant protein manufacturing capacity
Expansion of monoclonal antibody and recombinant protein manufacturing capacity is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11% a year, the consumable lines exposed to it move fastest: F-10 Serum Free Media compounds at 15.14%, taking its share of revenue from 6.43% to 9% and its value from USD 1.9 billion to USD 6.64 billion.
On the upside, the study's bull case assumes assumes biologics and cell/gene therapy manufacturing capacity expansions proceed on their announced timelines and serum-free media adoption accelerates faster than the base case, lifting both volume and average realised price across the forecast, which would take 2034 revenue to USD 79.7 billion rather than the USD 73.8 billion base case.
However, assumes a slowdown in cell and gene therapy commercialisation and continued fetal bovine serum supply and price volatility, delaying capacity additions and holding volume growth below the base case, which would hold 2034 revenue to USD 67.9 billion. Fetal Bovine Serum, which carries 19.86% of 2025 revenue, already grows at only 8.35% against the market's 11%, so the largest part of the base is also its slowest.
Key Players Compete on Fetal Bovine Serum Volume and F-10 Serum Free Media Growth
Competition in the global cell culture market runs along the consumable axis rather than the regional one. Fetal Bovine Serum holds 19.86% of 2025 revenue at USD 5.86 billion and remains the largest line through 2034 at 16%, making it the position hardest for a challenger to take. F-10 Serum Free Media, growing at 15.14%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 29.51 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Consumable | Fetal Bovine Serum | 19.86% · USD 5.86 billion | — |
| Product | Culture Systems | 32% · USD 9.44 billion | Cryostorage Equipment 17.83% |
| Application | Biopharmaceuticals | 34% · USD 10.03 billion | Gene Therapy 18.7% |
| End user | Pharmaceutical & Biotechnology Companies | 48% · USD 14.16 billion | Contract Research Organizations (CROs)/CDMOs 14.54% |
| Cell type | Mammalian Cell Culture | 88% · USD 25.97 billion | Non-Mammalian Cell Culture 12.92% |
- Based on regional analysis, North America led the global cell culture market in 2025 with 36.21% of global revenue at USD 10.69 billion, reaching USD 24.35 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 26.86% in 2025 to 32% in 2034, with revenue growing from USD 7.93 billion to USD 23.62 billion.
- Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 5% by 2034.
- F-10 Serum Free Media is projected to grow at 15.14% over the forecast period, the fastest of any consumable line.
- The United States is the largest single country market at USD 9.09 billion in 2025, 30.8% of global revenue.
The report segments the market across five axes; by consumable, and by product, application, end user and cell type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 67.9 billion and USD 79.7 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.